期刊文献+

阿扎胞苷联合HAG方案治疗不耐受强化疗的急性髓系白血病临床效果及安全性

Clinical Efficacy and Safety Analysis of Azacytidine Combined with HAG in the Treatment of Acute Myeloid Leukemia Intolerant to Intense Chemotherapy
下载PDF
导出
摘要 目的探讨阿扎胞苷联合高三尖杉酯碱+阿糖胞苷+粒细胞刺激因子(HAG)方案治疗不耐受强化疗的急性髓系白血病患者的临床效果及安全性。方法选取2020年3月至2023年6月收治的80例急性髓系白血病患者为研究对象,根据随机数字表法将其分为A、B、C3组。A组予单用阿扎胞苷(25例),B组予HAG方案(28例),C组予阿扎胞苷联合HAG方案(27例)。对比3组患者治疗后的总体有效率、外周血红细胞(中性粒细胞计数、血小板计数)、血红蛋白水平、中性粒细胞恢复时间、血小板恢复时间、血小板输注量及不良反应的发生情况。结果治疗后,C组患者总体有效率、外周血红细胞水平、血红蛋白水平、中性粒细胞恢复及血小板恢复时间均优于A、B两组(P<0.05);A、B两组的总体有效率、外周血红细胞、血红蛋白水平、中性粒细胞恢复时间及血小板恢复时间无明显差异(P>0.05),3组患者在不良反应的发生率血小板输注量方面无明显差异(P>0.05)。结论阿扎胞苷联合HAG方案治疗可提高急性髓系白血病患者治疗疗效,改善患者的血液指标及生活质量,且耐受性良好。 Objective To investigate the clinical efficacy and safety of azacytidine combined with hyperhartaxine+cytarabine+granulocytic stimulating factor(HAG)in the treatment of acute myeloid leukemia patients who are intolerant to intense chemotherapy.Methods A total of 80 AML patients admitted from March 2020 to June 2023 were selected as the study objects,according to the random number table,they were divided into three groups,A,B and C.Group A was given azacitidine alone(25 cases),group B was given HAG regimen(28 cases),and group C was given azacitidine combined with HAG regimen(27 cases).The overall response rate,peripheral blood cells(neutrophil,platelet),hemoglobin level and the occurrence of adverse reactions in 3 groups were compared after treatment.Results After treatment,the overall effective rate,peripheral blood cell level,hemoglobin level,neutrophil recovery and platelet recovery time in group C were better than those in groups A and B(P<0.05).There were no significant differences in the overall effective rate,peripheral blood cells,hemoglobin levels,neutrophil recovery time and platelet recovery time between groups A and B(P>0.05),and there were no differences in the incidence of adverse reactions and platelet infusion volume between the three groups(P>0.05).Conclusions Azacytidine combined with HAG regimen can improve clinical efficacy,blood indexes and quality of life of patients with acute myeloid leukemia,and it is well tolerated.
作者 侯先锋 HOU Xianfeng(Department of Hematology,Xinyi People's Hospital,Xinyi 221400,China)
出处 《中国医药指南》 2024年第9期98-100,共3页 Guide of China Medicine
关键词 急性髓系白血病 阿扎胞苷 HAG方案 总体有效率 外周血红细胞计数 不良反应 Acute myeloid leukemia Azacytidine HAG Overall response rate Peripheral blood cell count Adverse reaction
  • 相关文献

参考文献4

二级参考文献13

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部